All In Biotech

Drug Trial Radar · NCT06356311

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 473 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

473

Actual

Start

May 3, 2024

Primary completion

Oct 19, 2026

Study completion May 6, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).

Conditions

  • Gastroesophageal Cancer

Interventions

  • Sacituzumab tirumotecanBiological

    Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.

  • Trifluridine-TipiracilDrug

    Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.

  • IrinotecanDrug

    Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.

  • PaclitaxelDrug

    Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.

  • DocetaxelDrug

    Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.

  • Rescue medicationsDrug

    Participants are required to receive prophylactic mouthwash (steroid mouthwash \[dexamethasone or equivalent\] is highly recommended) to mitigate the onset and severity of stomatitis or oral mucositis. Additionally, participants may receive mucoadhesive hydrogel and oral nystatin suspension or other topical antifungal agents. Additional recommended rescue medications are histamine-1 (H1) receptor antagonist, H2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent, at the investigator's discretion.

  • Supportive care measuresDrug

    Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to ~ 31 months

Locations

168 sites in 24 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center ( Site 0119)

    Gilbert, Arizona

  • UCLA Hematology/Oncology - Santa Monica ( Site 0140)

    Los Angeles, California

  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0129)

    Orlando, Florida

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0108)

    Marietta, Georgia

  • University of Chicago Medical Center ( Site 0120)

    Chicago, Illinois

  • University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0124)

    Lexington, Kentucky

  • The University of Louisville, James Graham Brown Cancer Center-James Graham Brown Cancer Center ( Site 0113)

    Louisville, Kentucky

  • Norton Audubon Hospital-Norton Cancer Institute - Audubon ( Site 0105)

    Louisville, Kentucky

  • Henry Ford Hospital ( Site 0107)

    Detroit, Michigan

  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0138)

    Fargo, North Dakota

  • Oregon Health and Science University ( Site 0104)

    Portland, Oregon

  • UPMC Hillman Cancer Center ( Site 0126)

    Pittsburgh, Pennsylvania

  • MUSC Hollings Cancer Center-Hematology Oncology ( Site 0122)

    Charleston, South Carolina

  • Sanford Cancer Center ( Site 0136)

    Sioux Falls, South Dakota

  • The West Clinic, PLLC dba West Cancer Center ( Site 0110)

    Germantown, Tennessee

  • Inova Schar Cancer ( Site 0106)

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center ( Site 0111)

    Seattle, Washington

  • Institut Jules Bordet-GastroIntestinal Medical Oncology ( Site 1003)

    Anderlecht, Bruxelles-Capitale, Region de, Belgium

  • Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • UZ Leuven-Digestive Oncology ( Site 1000)

    Leuven, Vlaams-Brabant, Belgium

  • AZ Delta vzw ( Site 1002)

    Roeselare, West-Vlaanderen, Belgium

  • A. C. Camargo Cancer Center ( Site 0409)

    São Paulo, Brazil

  • IBCC - Núcleo de Pesquisa e Ensino ( Site 0402)

    São Paulo, Brazil

  • Centro de Pesquisa Clínica do Instituto do Câncer do Ceará ( Site 0405)

    Fortaleza, Ceará, Brazil

  • Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0406)

    Natal, Rio Grande do Norte, Brazil

  • Hospital de Caridade de Ijuí ( Site 0412)

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0400)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Hematologia e Oncologia ( Site 0404)

    Joinville, Santa Catarina, Brazil

  • Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0401)

    Barretos, São Paulo, Brazil

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0411)

    São José do Rio Preto, São Paulo, Brazil

  • McGill University Health Centre ( Site 0201)

    Montreal, Quebec, Canada

  • James Lind Centro de Investigacion del Cancer ( Site 0506)

    Temuco, Araucania, Chile

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0503)

    Santiago, Region M. de Santiago, Chile

  • FALP-UIDO ( Site 0500)

    Santiago, Region M. de Santiago, Chile

  • Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 0502)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 0501)

    Santiago, Region M. de Santiago, Chile

  • Anhui Provincial Cancer Hospital-medical oncology ( Site 3016)

    Hefei, Anhui, China

  • Second Affiliated hospital of Anhui Medical University-Oncology ( Site 3038)

    Hefei, Anhui, China

  • Chongqing University Three Gorges Hospital ( Site 3036)

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital ( Site 3007)

    Fuzhou, Fujian, China

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.